Form 4: Monte Rosa Therapeutics COO Jennifer Champoux Reports Acquisition of Shares and Stock Options

Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics, reports the acquisition of 30,000 shares of common stock and 135,000 stock options.

Summary

• On January 2, 2025, Jennifer Champoux, the Chief Operating Officer of Monte Rosa Therapeutics, acquired 30,000 shares of common stock.
• These shares were granted as restricted stock units (RSUs) under the company's 2021 Stock Option and Incentive Plan.
• Each RSU represents the right to receive one share of Monte Rosa Therapeutics' common stock upon vesting and settlement.
• 25% of the RSUs will vest on January 1, 2026, with the remaining RSUs vesting in three equal annual installments thereafter, contingent upon continued service.
• Champoux also acquired stock options for 135,000 shares with an exercise price of $7.11.
• 25% of these options will vest and become exercisable on January 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, also subject to continued service.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options to the COO aligns her interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Future Outlook

The vesting schedules for the RSUs and stock options suggest an expectation of continued service and contribution from the COO over the next several years.

Industry Context

Stock option and RSU grants are common practice in the biotech industry to incentivize and retain key executives. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Similar grants are common among comparable biotech companies such as Arvinas, Kymera Therapeutics, and Nurix Therapeutics.
• The vesting schedules are in line with industry standards, typically ranging from three to four years with a one-year cliff.
• The exercise price of $7.11 for the stock options would be considered at-market if it reflected the stock's fair market value at the time of the grant.

Stakeholder Impact

• Shareholders may view the grants positively as they align management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates